跳转到主要内容

Introduction

The American Society of Plastic Surgery announced: 2.7 million noninvasive procedures were done in 2017 for skin filling. HA is one of the most used fillers - resorbable, temporary and very well tolerated. Vascular occlusion is a rare complication that can occur by local compression or accidental intraarterial injection of filler. It can happen with any injector, as the face arteries anatomy vary among people. There is no consensus on treatment, which may include early degradation with hyaluronidase (HYAL) for embolus dissolution.


Objectives

Evaluate the treatment of vascular occlusion after facial filling with hyaluronic acid an suggest a treatment protocol according to the time of evolution.




Method

A case series made by the review of medical records of 8 patients who developed vascular occlusion after HA filling. Variables included: sex, age, site of occlusion, HA and HYAL volume, associated medications, time to start treatment and time to resolve the condition.


Results




Sample characteristics and variables included are in Table 1 - mean age: 30,75 y. Different regions were affected (Graphic 1). The time for HYAL onset in each patient were different, as the time for total resolution (Graphic 2). Different oral medications (OM) were used. All patients had complete resolution. Pictures 1 to 8 show the cases.


Conclusion

Early recognition and immediate degradation with HYLA are key points in reestablishing blood flow after vascular occlusion with HA. The sooner HYLA is initiated, the better. HYLA’s dose is not fixed, varying accordingly to the area and amount of HA used. Different OM were associated, which may have influenced the outcomes.

被标记: 针剂注射

评价这篇文章

分享这篇文章于

关于作者

Ritha DE CASSIA CAPELATO ROCHA 医师

Ritha DE CASSIA CAPELATO ROCHA 医师

皮肤科医师, 巴西

Vivian TREIN CUNHA SIMOES PIRES 医师

Vivian TREIN CUNHA SIMOES PIRES 医师

皮肤科医师, 巴西

评论

与 IMCAS 社区建立联系!

有关发表

Case Series of Vascular Occlusions after HA Filling

发表于 2019年 11月 1日

Case Series of Vascular Occlusions after HA Filling

Management of masseter hypertrophy and bruxism with Botulinum Toxin A

发表于 2021年 11月 26日

Management of masseter hypertrophy and bruxism with Botulinum Toxin A

Using a needle versus cannula: the advantages and disadvantages

发表于 2020年 9月 18日

Using a needle versus cannula: the advantages and disadvantages

处理中,请稍候...

错误

请填写所有必填字段。以下是缺失的字段: